Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302161 | 0.88 | MAPT (0.43) | MAPTSMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL13302154 | 0.82 | PTPN1 (0.49) | MAPTSMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL22044207 | 0.80 | ATM (0.55) | MAPTSMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL13302165 | 0.79 | DYRK1A (0.56) | PRKD3CCNB2CDK1PIM1CCNB1 | |
| SCHEMBL31001028 | 0.77 | CYP1A2 (0.52) | MAPTALDH1A1CYP1A2CYP3A4NPSR1 | |
| SCHEMBL21693353 | 0.76 | ATM (0.59) | MAPTSMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL3132450 | 0.76 | PDGFRB (0.56) | MAPTCYP1A2NPSR1ATMDHFR | |
| SCHEMBL13302160 | 0.76 | HTT (0.44) | MAPTSMN1; SMN2ALDH1A1KDM4ENR4A2 | |
| SCHEMBL13302379 | 0.75 | MAPT (0.51) | MAPTSMN1; SMN2ALDH1A1LMNACYP1A2 | |
| SCHEMBL5178631 | 0.75 | ALDH1A1 (0.47) | ALDH1A1CYP1A2DHFRKDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | MAPT 2/4885SMN1; SMN2 141/4885ALDH1A1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.